

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE	9
Background	9
Objective and Scope	9
Selection of Topics for Monographs	10
Data for Monographs	11
The Working Group	11
Working Procedures	11
Exposure Data.....	12
Studies of Cancer in Humans	14
Studies of Cancer in Experimental Animals.....	17
Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms.....	20
Summary of Data Reported	22
Evaluation	23
References.....	27
OVERALL INTRODUCTION	35
1. Nomenclature	37
1.1 Activity	37
1.2 Energy	38
1.3 Exposure	39
1.4 Dose	39
2. Dosimetric methods and models.....	42
2.1 Occupational setting	43
2.1.1 Doses from external irradiation	43
(a) External β - and γ -rays	43
(b) Neutrons	44
2.1.2 Doses from internal irradiation	45
2.2 Environmental setting	45
2.2.1 Environmental measurements	46
(a) Ambient radiation	46
(b) Radionuclides	47

2.2.2	Environmental modelling	47
	(a) Doses from external irradiation	47
	(b) Doses from internal irradiation	49
2.3	Medical setting	50
2.4	Retrospective dose assessment	51
3.	Transmission and absorption in biological tissues	52
3.1	Track structure of radiation with low and high linear energy transfer	52
3.2	Quantitative characterization of energy deposition at cellular and subcellular sites	53
3.3	'Low dose'	56
3.4	Clusters of energy deposition events and correlation with biological lesions	57
3.5	Biological effects of low doses.....	57
4.	Occurrence and exposure	59
4.1	Military uses	59
4.1.1	Detonation of atomic bombs over Hiroshima and Nagasaki.....	59
4.1.2	Nuclear weapons testing	60
	(a) Doses from local fall-out	62
	(b) Doses from tropospheric and global fall-out	63
4.1.3	Production of materials for nuclear weapons	63
	(a) The Kyshtym accident	65
	(b) The Windscale accident	65
4.2	Medical uses	66
4.2.1	Diagnostic radiology	68
4.2.2	Diagnostic nuclear medicine	70
4.2.3	Radiation therapy.....	70
4.3	Occupational exposure	72
4.3.1	Natural sources (excluding uranium mining)	72
4.3.2	Man-made sources	74
	(a) Medical profession.....	74
	(b) Commercial fuel cycle	75
	(c) Industrial sources	75
	(d) Military activities	76
4.4	Environmental exposure	78
4.4.1	Natural sources	78
	(a) Cosmic radiation	78
	(b) Terrestrial radiation	87
4.4.2	Man-made sources	95
	(a) Routine releases from facilities	95
	(b) Accidents	96

(c) Miscellaneous releases	99
4.5 Summary	100
5. Deterministic effects of exposure to ionizing radiation	101
5.1 Dose–survival relationships	102
5.2 Time–dose relationships	105
5.2.1 Dose rate	105
5.2.2 Dose fractionation	105
6. References	107
THE MONOGRAPHS	117
X-radiation and γ-radiation	121
1. Exposure data	121
1.1 Occurrence	121
1.1.1 X-radiation	121
1.1.2 γ -radiation	122
1.2 Exposure	122
1.2.1 Natural sources	123
1.2.2 Medical uses	125
1.2.3 Nuclear explosions and production of nuclear weapons	126
1.2.4 Generation of nuclear power	128
1.2.5 Accidents	128
1.2.6 Occupational groups	129
1.2.7 Summary of collective effective doses	133
1.2.8 Variations in exposure to X- and γ -radiation	134
1.3 Human populations studied in the epidemiology of cancer due to X- and γ -radiation	134
1.3.1 Unselected populations	134
1.3.2 Workers	138
1.3.3 Patients	138
2. Studies of cancer in humans	138
2.1 Introduction	138
2.2 Military uses	142
2.2.1 Detonation of atomic bombs over Hiroshima and Nagasaki	142
(a) Leukaemia	146
(b) All solid tumours	148
(c) Site-specific cancer risks	150
2.2.2 Nuclear weapons testing	152
(a) People living near weapons test sites	152
(b) Military personnel participating in weapons tests	153
2.2.3 Production of materials for nuclear weapons	154

2.3	Medical uses	156
2.3.1	Radiotherapy for malignant disease	156
	(a) Cervical cancer.....	156
	(b) Hodgkin disease	167
	(c) Breast cancer	168
	(d) Ovarian cancer	169
	(e) Testicular cancer.....	170
	(f) Malignant disorders during childhood.....	170
	(g) Bone-marrow transplant.....	172
2.3.2	Radiotherapy for benign disease	172
	(a) During adulthood	180
	(b) During childhood	183
2.3.3	Diagnostic X-irradiation	185
	(a) During adulthood	185
	(b) During childhood	191
2.4	Occupational exposure	192
2.4.1	Medical use of radiation	193
2.4.2	Clean-up of the Chernobyl nuclear reactor accident.....	194
2.4.3	Nuclear industry workers.....	195
	(a) United Kingdom.....	195
	(b) USA	198
	(c) Russian Federation.....	199
	(d) International collaborative study	199
2.4.4	Various occupations	200
2.5	Environmental exposure	200
2.5.1	Natural sources	200
2.5.2	Releases into the environment.....	206
	(a) The Chernobyl accident	206
	(b) Populations living around nuclear installations.....	207
2.6	Issues in quantitative risk assessment	209
2.6.1	Measures of risk.....	209
2.6.2	Problems and uncertainties in quantifying risks due to radiation	211
2.6.3	Lifetime risk estimates by national and international committees	213
	(a) UNSCEAR.....	213
	(b) Committee on the Biological Effects of Ionizing Radiations (BEIR V; 1990)	214
	(c) ICRP.....	215
	(d) Summary	216
2.6.4	Estimates of risk due to specific sources of radiation.....	216
	(a) Natural background	216

	(b) Medical diagnosis	218
	(c) Dental radiography.....	219
	(d) Mammography	219
2.7	Other issues in epidemiological studies	220
2.7.1	Scale of measurement	221
2.7.2	Complicating factors	221
	(a) Dose	222
	(b) Dose rate	226
	(c) Age	227
	(d) Sex	227
	(e) Time	228
	(f) Co-factors.....	229
2.7.3	Variations in risk by cancer site.....	230
	(a) Excess relative risk	230
	(b) Absolute excess risk.....	230
	(c) Attributable risk	232
	(d) Relative tissue sensitivity.....	232
3.	Studies of cancer in experimental animals	233
3.1	Carcinogenicity in adult animals	233
3.1.1	Mice	233
3.1.2	Genetically engineered mice	238
3.1.3	Rats	239
3.1.4	Rabbits	241
3.1.5	Dogs.....	241
3.1.6	Rhesus monkeys	241
3.2	Prenatal exposure	242
3.2.1	Mice	242
3.2.2	Dogs.....	245
3.3	Parental exposure	245
4.	Other data relevant to an evaluation of carcinogenicity and its mechanisms	247
4.1	Radiation syndromes: Early effects of whole-body irradiation	247
4.2	Late deterministic effects of ionizing radiation	249
4.2.1	Skin	250
4.2.2	Lung.....	253
4.2.3	Gonads	254
	(a) Ovary	254
	(b) Testis.....	254
4.2.4	Kidney	257
4.2.5	Gastrointestinal tract	258
	(a) Oral cavity	258
	(b) Oesophagus	258

	(c) Stomach	258
	(d) Small intestine	258
	(e) Large intestine	259
4.2.6	Haematopoietic system	259
4.2.7	Central nervous system	261
4.2.8	Thyroid.....	263
4.2.9	Eye	263
4.3	Radiation-sensitive disorders	265
4.3.1	Ataxia telangiectasia	265
	(a) <i>ATM</i> gene and gene product	265
	(b) <i>ATM</i> and cell-cycle checkpoint control	266
	(c) Sensitivity to ionizing radiation	267
	(d) Cancer in patients with ataxia telangiectasia	267
	(e) <i>ATM</i> mutations in cancers in patients without ataxia telangiectasia	269
	(f) Radiosensitivity, <i>ATM</i> mutation and cancer risk in people heterozygous for <i>ATM</i>	270
	(g) Cancer risk in <i>Atm</i> ^{-/-} mice	271
4.3.2	Nijmegen breakage syndrome	272
4.3.3	Human severe combined immunodeficiency syndromes	273
4.3.4	Adverse responses to radiotherapy	274
4.3.5	Tumour suppressor gene disorders	276
	(a) Humans	276
	(b) Experimental models	278
4.4	Genetic and related effects	280
4.4.1	Humans	280
	(a) Natural background radiation	280
	(b) Survivors of the atomic bombings	281
	(c) Chernobyl accident	281
	(d) Accident at Goiânia (Brazil)	283
4.4.2	Experimental systems	283
	(a) Mutations <i>in vivo</i>	283
	(b) Studies <i>in vivo/in vitro</i>	290
	(c) Cellular systems	291
5.	Summary of data reported and evaluation	299
5.1	Exposure data	299
5.2	Human carcinogenicity data	299
5.3	Animal carcinogenicity data	301
5.4	Other relevant data	301
5.5	Evaluation	305
6.	References	305

Neutrons	363
1. Exposure data	363
1.1 Occurrence	363
1.2 Relative biological effectiveness	364
1.3 Exposure	367
1.3.1 Natural sources	367
1.3.2 Medical uses	371
1.3.3 Nuclear explosions.....	372
1.3.4 Occupational exposure.....	372
1.4 Summary	374
2. Studies of cancer in humans	376
3. Studies of cancer in experimental animals	377
3.1 Adult animals	377
3.1.1 Mouse.....	377
3.1.2 Rat	388
3.1.3 Rabbit.....	396
3.1.4 Dog	396
3.1.5 Rhesus monkey	397
3.1.6 Relative biological effectiveness	397
3.2 Prenatal exposure	397
3.3 Parental exposure	400
4. Other data relevant to an evaluation of carcinogenicity and its mechanisms	400
4.1 Transmission and absorption in biological tissues	400
4.2 Adverse effects other than cancer.....	401
4.2.1 Modifying factors	402
(a) Dose rate and fractionation	402
(b) Effect of oxygen.....	402
(c) Cell cycle	402
4.2.2 Effects in normal tissues	403
(a) Skin	403
(b) Gastrointestinal tract	403
(c) Haematopoietic system	405
(d) Central nervous system	406
(e) Reproductive system	406
(f) Renal system	407
(g) Respiratory system.....	407
(h) Ocular lens	407
4.3 Radiation-sensitivity disorders	409
4.4 Genetic and related effects	410
4.4.1 Humans	410
4.4.2 Experimental systems	412

(a) Mutations <i>in vivo</i>	412
(b) Cellular systems	416
5. Summary of data reported and evaluation	429
5.1 Exposure data	429
5.2 Human carcinogenicity data	429
5.3 Animal carcinogenicity data	429
5.4 Other relevant data	430
5.5 Evaluation	431
6. References	432
GLOSSARY	449
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	459

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.